#1Full-Year Results 2020 Pierre-Alain Ruffieux, CEO Rodolfo Savitzky, CFO 27 January 2021 Lonza Hong Kong Aerial scene in night, with road and traffic#2Contents Full-Year 2020 Corporate Overview Full-Year 2020 Financial Summary Lonza Segments: ⚫ Pharma Biotech & Nutrition (LPBN) . Specialty Ingredients (LSI) Outlook 2021 and Mid-Term Guidance 2023 Q&A Appendices Urban crowd from above#3Full-Year 2020 Corporate Overview 2 C 60 (W) FOO Lonza Aerial view of dependence monument in Mexico City#4Full-Year 2020 Corporate Overview Strong full-year performance, driven by sales growth in LPBN Lonza delivers on guidance with 12.0%² sales growth, with CHF 4.5 billion sales, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as Specialty Ingredients (LSI) is reported as a discontinued operation Strong performance in LPBN with 12.2%² sales growth and CORE EBITDA margin of 32.1%, driven by Biologics business Production of the drug substance for Moderna COVID-19 Vaccine has commenced at Portsmouth (USA) and Visp (CH) sites LSI³ delivered a solid performance, with 3.4%² sales growth alongside an improved CORE EBITDA margin, reported at 20.3%4 Winding road at Faroe 12020 Guidance relates to Lonza Group results without LSI reported as discontinued operations 2 All sales growth figures are at a constant exchange rate (CER) 3 Specialty Ingredients Business (excluding Corporate/carve-out and divestiture costs directly attributable to LSI) 4 CORE EBITDA margin at a constant exchange rate (CER) CORE definition: See appendix 4#5Updated Business Structure A clear organizational design for a single business operating in a single industry Divisions Office of the CEO LPBN SEGMENT (FUTURE LONZA) CEO Corporate Functions Functions LSI SEGMENT (DISCONTINUED OPERATIONS) Specialty Ingredients Capsules and Small Health Biologics Molecules Ingredients Cell & Gene Therapy, and Bioscience Operations Quality Commercial/ Marketing Human Finance Resources Microbial Control Solutions Specialty Chemical Solutions P&L accountability End-to-end delivery to customers Business model to create competive edge Global standards, processes and best practices Functional strategies Partnership approach to divisional support 5#6Lonza - Four Divisions A structure developed to improve synergies and meet customer needs Capsules and Health Ingredients Capsules Health Ingredients Small Molecules Biologics Mammalian Microbial Active Pharmaceutical Ingredients Drug Product Formulation Licensing Bioconjugates Drug Product Services mRNA Cell & Gene Therapy, and Bioscience Cell & Gene Therapy Personalized Medicines Bioscience 6#7New EC Members An expanded leadership team to ensure divisional representation, effective as of 1 April 2021 Pierre-Alain Ruffieux Chief Executive Officer Existing Members Rodolfo J. Savitzky Caroline Barth Chief Financial Officer Chief Human Resources Officer Stefan Stoffel Chief Operating Officer New Members Claude Dartiguelongue Capsules and Health Ingredients Gordon Bates Small Molecules Jean-Christophe Hyvert Biologics/Cell & Gene Therapy, and Bioscience 7#8Cardriving on a road in between tulip fields as seen from above LSI Segment Divestment in Progress Signing of divestment deal expected in Q1 2021 Initial expressions of interest from potential buyers were received in 2020 We have selected a short list of bidders for a second phase of the process. Identities of bidders cannot be revealed for confidentiality reasons We expect to sign a deal in Q1 2021 8#9Long-Term Growth Supported by Continued CAPEX Investments An overview of major projects in 2020 Bend, USA Small Molecules . • Oral Inhalation Particle Engineering Portsmouth, USA Biologics • mRNA suites • Mid-scale mammalian manufacturing Hayward, USA Biologics · Small-scale mammalian manufacturing Houston, USA Cell & Gene Therapy 1 Capsules manufacturing capacity expansion across 8 global sites 2 Under construction, operational Q2/Q3 2021 Greenwood, USA Capsules¹ Tampa, USA Small Molecules HPAPI Geleen/Maastricht, NL Cell & Gene Therapy Basel/Stein, CH Drug Product Services labs Tuas, SG Biologics New facility Expansion New technology Nansha, CN Small Molecules . ΑΡΙ Visp, CH Biologics • • mRNA suites Parenteral fill and finish Bioconjugation Mid-scale microbial manufacturing Small- and large-scale mammalian manufacturing Small Molecules API and HPAPI Guangzhou, CN2 Biologics • Small-scale mammalian manufacturing 9#10Our Business in the COVID-19 Pandemic Our work to control and contain the pandemic Business continuity maintained through rigorous protection measures and due to our classification as an essential supplier LPBN is working to support a broad range of customers. developing vaccine candidates, treatments and therapies related to COVID-191 Sixteen microbial control solutions produced by LSI were approved by US EPA² to eradicate COVID-19 on surfaces AstraZeneca moderna 00000 君实生物 TopAlliance ༠༩ Humanigen altimmune The logos constitute a selection of customers who are collaborating with Lonza on COVID-19 projects. In total, Lonza has received more than 200 enquiries related to COVID-19 projects 2 United States Environmental Protection Agency 10#11Manufacturing the Moderna COVID-19 Vaccine Supporting accelerated vaccine production to control the pandemic 10-year collaboration agreement with Moderna on mRNA platform, including the manufacture of the drug substance for Moderna COVID-19 Vaccine Eight months turnaround from contract negotiation to commencement of manufacture Demonstrates the commercial value of the Ibex Solutions offering (and pre-investment in facilities) Showcases Lonza's capability to address customer challenges of speed and scale 11#12Full-Year 2020 Financial Summary Lonza Vineyards by the lake - Lavaux, Switzerland#13Financial Highlights Strong business fundamentals deliver double-digit sales growth FY 2020 CHF million Change CER Change AER Sales CORE EBITDA 4,508 12.0% 7.2% 1,406 9.1% 5.4% CORE EBITDA margin 31.2% (0.8ppts) (0.5ppts) * Changes in CER and AER based on restated 2019 figures, reflecting the classification of Specialty Ingredients as discontinued operations Strong sale growth momentum continues across businesses Strategic growth projects impact CORE EBITDA margin by -1.2ppt (-0.4ppts YoY) Efficiency programs partially mitigate investments impact Adverse FX impact on margins are partially mitigated by natural hedges CORE definition: See appendix 13#14CORE EBITDA Margin Drivers Productivity measures mitigate ramp-up costs CORE EBITDA margin FY20191 31.7% Growth project ramp-up Cost control and operational exelence Business mix CORE EBITDA margin FY2020 31.2% 1 Restated to reflect the classification of Specialty Ingredients as discontinued operations Upfront hiring for growth projects in launch/ramp-up phase Reduced admin costs through productivity measures and COVID-19 tailwinds (e.g., travel) Continued focus on operational excellence in manufacturing operations - Investments in high-growth businesses like Cell & Gene Therapy and Personalized Medicine CORE definition: See appendix 14#15Operational Free Cash Flow Robust cash flow generation despite higher CAPEX FY 2020 YoY change CHF million FY 2019 (Restated)1 Maintained target level of receivable and payable days EBITDA 1,378 114 1.264 Change of operating net working (260) (26) (234) capital (NWC) Opportunity to further optimize inventory CAPEX (889) (196) (693) Other 275 241 34 Accelerated deployment of CAPEX against additional initiatives Operational free cash flow² 504 133 371 YE NWC as % sales 15.9% 0.0ppts 15.9% CAPEX as % sales 19.7% 3.2ppts 16.5% Increased customer funding for selected growth projects 1 Restated to reflect the classification of Specialty Ingredients as discontinued operations 2 Before acquisitions 15#16CAPEX Investments to support growth CHF million LHO Maintenance 19.7% 889 16.5% 693 2019 2020 Base Growth Projects Strategic Growth Projects Total as % Sales Bridge crossing over lake Konstanz, Germany * 2019 figures have been restated to reflect the classification of Specialty Ingredients as discontinued operations Around 70% of CAPEX in growth projects across businesses and geographies CAPEX intensive projects mainly in Mammalian manufacturing Attractive IRR>25% and ROIC >30% on ramped-up sales Investments de-risked through partially contracted demand 16#17Leverage Profile Strong balance sheet to support growth investments Net Leverage (Net Debt/ Core EBITDA)¹ 2,3x 2018 Boats moored behind a pier, Hong Kong 1 Based on Lonza Group figures 1,8x 1,6x 2019 2020 Deleveraging behind CORE EBITDA growth and strong operating cash Funding sources diversified with inaugural Eurobond Maturity profiles extended and financing costs reduced Ample headroom for growth investments Commitment to strong investment grade rating CORE definition: See appendix 17#18CHF million ROIC Increasing ROIC despite growth investments FY 2020 YoY change FY 2019 (Restated)1 Net Operating Profit Before Taxes 949 6.3% 893 Taxes 8.8% (1.1ppts) 9.9% (in % of Net Op. Profit Before Taxes) NOPAT 865 7.5% 805 Average Invested Capital 9,019 2.6% 8,788 ROIC 9.6% 0.4ppts 9.2% 1 Restated to reflect the classification of Specialty Ingredients as discontinued operations Operating Profit Before Taxes impacted by limited depreciation increase Lower tax rate for Lonza continuing due to country profit mix and one- time impacts Increased Invested Capital behind CAPEX investments 18#19Lonza Pharma Biotech & Nutrition (LPBN) Lonza Lonza#20grun NORTH 8Y15 sev Full-Year 2020 LPBN Performance Overview Performance driven by YoY sales growth and margin increase Strong full-year performance, driven by Biologics business All businesses managed COVID-19 impacts and maintained business continuity Businesses have worked to expand their service offerings and manufacturing capacity Sales growth momentum expected to continue into 2021 New divisional structure implemented from 1 January 2021. New financial reporting structure will commence from H1 2021 20 20#21New LPBN Customer Projects Announced in 2020 Selected Lonza customers in the healthcare sector moderna SURROZEN SERVIER LamKap Bio HELPING THE BODY TO FIGHT CANCER AstraZeneca Aurinia Stanford MEDICINE YPSOMED SELFCARE SOLUTIONS Y Humanigen KODIAK ANTHOS THERAPEUTICS rocket pharma INDAPTA THERAPEUTICS NOGA THERAPEUTICS .:: isoplexis BE THE MATCHⓇ Rapidly scaling up a new vaccine modality Supporting a broad range of customers developing vaccines and therapies related to COVID-19 Signing a series of strategic contracts for IbexⓇ Dedicate, including microbial and bioconjugates Providing full-value chain for complex molecules such as antibody-drug conjugates (HPAPI, mAb, linker and conjugation) Business growth in CGT supported by new customer wins * Source: Company internal information and publically available sources 21#22Waterfall In Forest, Lenk Switzerland Refreshed Focus on Sustainability Sustainability as a critical component of our customer value proposition Environmental stewardship • Around 10% of all electrical energy comes from renewable sources . Around 10% decrease in Industrial water intensity (water use / sales) since 2018 Year-on-year progress in reducing energy consumption and carbon footprint Societal contribution • • • Establishment of employee Diversity and Inclusion Taskforce 34,000 safety improvements in 2020, bringing lost-time injuries to an all-time low Community investment during COVID-19: provision of disinfectant and PPE to hospitals in Switzerland and the US, and supporting critical hygiene projects in India 22 22#23Market Small Molecules Lonza Operations Growth driven by: Oncology (with a focus on Highly Potent API) Specialized medicines (with US and Europe showing high demand) Trend for small companies owning majority of clinical pipeline continues - with high propensity to outsource Speed to market is a focus as more than half of new market approvals are on an accelerated pathway COVID-19 impacts have been managed with supply chain planning and virtual customer engagement New project acquisition supported by high brand equity and strong contracting trends New service offerings launched in 2020 include Solid Form Services and Inhalation New growth investments approved to support customers in early phase development and to manage high capacity utilization in existing assets Financial Performance1 High single-digit sales growth across 2020 Margin growth resulting from leveraged performance and sales growth Double-digit sales growth forecast expected in 2021 from new customer contracts 1 Comparison versus 2019 at a constant exchange rate (CER) 23#24Market Biologics Lonza Operations Continued strong demand for large- scale mammalian capacity Strong growth in trend towards outsourcing: Mammalian (pipeline dominated by small and mid-sized biotechs) Bioconjugates (demand for specialized facilities and knowledge) More than 500 drugs under investigation for COVID-19 in more than 1,360 clinical trials - CDMOs are playing a key role 1 Comparison versus 2019 at a constant exchange rate (CER) Overall contracting was strong: YoY increase in new customers and new program sign-ups High interest and new deals signed for Ibex® Dedicate, and customer base secured for mid-scale microbial capacity expansion High utilization of asset footprint, across clinical and commercial (small to large scale) Continued capacity expansion in 2021 across drug substance and product services Well-managed COVID-19 situation despite some limited supply and manufacturing risks Financial Performance¹ Strong double-digit (mid-teens) sales growth across 2020, driven by strong demand in all technologies Lower margin, driven by higher OPEX, related to growth projects 2021 expected to show third year of strong double-digit growth, mainly driven by strategic growth initiatives (P6, Ibex and Guangzhou) 24#25Cell & Gene Therapy (CGT) Market Continued strong market growth, with focus on regenerative treatments for COVID-19 Some non-COVID-19 therapies have been deprioritized Rapid pipeline expansion in 2020: >2,000 active therapies in development >1,100 regenerative medicine clinical trials Five landmark commercial approvals in the last two years Cost of production remains a challenge Lonza Operations Business continuity maintained through pandemic, agreement with new customer Altimmune allows for the supply of AdCOVID, a single-dose intranasal vaccine for COVID-19 Strong demand for our products and services New customer agreements have enabled differentiated service offerings in emerging modalities (e.g. partnership with BeTheMatch for apheresis networks management and cellular source material) Vein-to-vein supply chain network has been expanded to support CGT customers needs beyond manufacturing Financial Performance¹ Strong sales growth above the market, supported by solid demand from new and existing clients Margin and operational improvement through increased throughput on existing assets 2021 margin improvement anticipated through efficiency improvements and higher asset utilization 1 Comparison versus 2019 at a constant exchange rate (CER) 25#26Bioscience Market Solid demand across all customer groups COVID-19 shutdowns caused reduced demand in Q2 from academic and research institutes, followed by recovery to pre-COVID- 19 levels in Q3 and Q4 Pandemic created some supply chain challenges (raw materials supply and increased global freight costs) Lonza Operations All sites remained operational through pandemic and new raw material sources and alternative freight channels have been identified to buffer COVID-19 impacts in 2021 Satisfactory organic growth rates in 2020 and a return to strong growth in testing, (after a flat 2019) Review of commercial operations to focus on best-fit markets and planned digital investments will deliver an enhanced customer experience and improved operational efficiency Financial Performance¹ High single-digit sales growth across 2020 (driven by Media and MODA) Strong margin improvement was driven by operation efficiency 2021 forecast of low double-digit sales growth, supported by digital investment, innovation and strong customer relationships 1 Comparison versus 2019 at a constant exchange rate (CER) 26 26#27Market Capsules & Health Ingredients (CHI) Lonza Operations Nutraceutical market • Continued growth driven by end- consumer demand for health ingredients and supplements. This trend was accelerated in 2020 by the COVID-19 pandemic Pharmaceutical market Flat to negative growth driven by lower use of prescription drugs as patients deferred elective medical treatments due to COVID-19 Partially offset by increased demand for selected OTC medications Global CHI network maintained essential operations in all geographies, serving existing customers with minimal disruption High capacity utilization across capsule product portfolio led to increased lead times for selected capsule products Capacity investment approved in 2020, increasing total production capacity by 15% by the end of 2021 Financial Performance¹ High single-digit sales growth in 2020 and stable margin • Business growth driven by nutritional capsules and ingredients Pharmaceutical capsules sales growth was flat to low single-digits Low single-digit growth anticipated in H1 2021, due to expected capacity constraints and increased customers' inventory 1 Comparison versus 2019 at a constant exchange rate (CER) 27#28Lonza Specialty Ingredients (LSI) (Discontinued operation) Lor Lonza#29Full-Year 2020 LSI Performance Overview Overall margin improvement as cost increases were offset by higher demand Specialty Ingredients (LSI)¹ delivered a strong performance, with 3.4% CER sales growth alongside an improved CORE EBITDA margin, reported at 20.3%2 Impacts of COVID-19 were largely managed across the business portfolio High demand for disinfection solutions from Microbial Control Solutions division to support in managing the COVID-19 pandemic Lonz Carve-out finalized, portfolio showed resilience in top and bottom line, efficient strategy and market-oriented organization in place. 1 Speciality Ingredients Business (excluding Corporate/carve-out and divestiture costs directly attributable to LSI) 2 CORE EBITDA margin at a constant exchange rate (CER) CORE definition: See appendix 29#30Microbial Control Solutions Hygiene Very strong performance, driven by quarternary (quat) ammonium compounds and formulated products Significant long-term contracts secured Home & Personal Care Solid growth in preservation and laundry Long-term contracts secured with suppliers and customers Reduced market demand in Skin & Hair Care, and Food businesses Wood Protection Increased demand and new business picked up, leading to a strong performance Positive retail and Do It Yourself (DIY) business Paints & Coatings Negatively impacted by COVID-19 pandemic, especially in Dry-Film Application Material Protection Adverse market environment Increased demand in Oil & Gas and Metal Protection in H2 expected to continue into 2021 Crop Protection Lower global demand in Agro Specialties as a result of COVID-19, considered as a one-off event Geographical expansion to North America, LATAM and SEA 30#31Specialty Chemical Services Composite Materials Solid demand in industrial sector for construction and protective coatings Strong project pipeline in Asia for electronics applications Civil aviation and electronics sectors negatively affected by COVID-19 Demand for telecommunication infrastructure materials expected to improve in H1 2021 CDMO Successful scale up of new projects in Visp (CH) Major CDMO contract for highly innovative new battery materials, impact expected in 2021 Fermentation growth strategy shows first results, with further growth anticipated in 2021 Performance Intermediates & Chemicals Overall good performance driven by increased volumes and prices of Vitamin B3 Consumer electronics business and industrial applications slowed down, negatively impacting PMDA Solid demand expected across most markets in H1 2021, and some recovery in industrial applications 31#32Outlook 2021 and Mid-Term Guidance 2023 -- Lonza Drone point view of city street crossing at rush hour#33Outlook 2021 Another year of low double-digit CER sales growth driven by sustained strong momentum across businesses CORE EBITDA margin improvement in-line with 2023 Mid- term Guidance trajectory Low double-digit CER sales growth Outlook assumes no significant adverse impact on demand and no major disruptions in supply chain or business operations from COVID-19 CORE EBITDA margin improvement in-line with Mid-Term Guidance CORE definition: See appendix 33#34Mid-Term Guidance 2023 Double-digit sales growth per year driven by Biologics, Small Molecules and Cell & Gene Therapy businesses Double-digit sales growth per year - 33% - 35% CORE EBITDA margin Improved CORE EBITDA margin despite investments in growth projects Double-digit ROIC driven by growth and margin expansion Double-digit ROIC CORE definition: See appendix 34#35Lonza Priorities 2021 Setting up the future Lonza business for continued growth Successful completion of divestment of LSI segment and review of plans for sales proceeds Focus on maintaining business continuity through pandemic and execution of growth projects Establish and strengthen systems and processes in the new business structure to optimize efficiency and delivery Continued levels of CAPEX investment to deliver sustained growth and meet customer demand Focus on talent attraction to support new CAPEX investments coming on line Continued review of environmental, social and governance (ESG) measures. under new and expanded leadership 35#36Q&A P Lonza and bus traffic on road intersection at night in Hong Kong downtown district,#37Appendices Lonza LIPS HARY Aerial view of international port in Hong Kong#38Sales in CHF million 5,542 5,083 4,132 3,584 3,640 3,803 Lonza Financial Performance Trends from 2013 to 2020 CORE EBITDA in CHF million 27.3 31.2 26.5 31.7 1.406 1,334 4,508 % Margin 4,207 22.2 1,349 20.4 20.9 19.8 918 711 743 793 2013 2014 2015 2016 2017 pro- forma 2018 restated² 2019 restated³ 2020 CORE RONOA in % 21.5 16.4 14.3 12.3 32.1 31.4 30.0 28.9 2013 2014 2015 2016 2017 2018 2019 restated³ 2020 Reported pro-forma 2017 financial results (restated for IFRS 15) include Capsugel full-year 2017 financial result 2 Restated 2018 financial results reflect the classification of Water Care business as discontinued operations 3 Restated 2019 financial results reflect the classification of Specialty Ingredients as discontinued operations 2013 2014 2015 2016 2017 pro- forma¹ 2018 restated² 2019 restated³ 2020 CORE EPS Diluted in CHF 5.0 50 12.0 12.2 11.4 10.8 8.4 6.8 6.8 2013 2014 2015 2016 2017 2018 2019 2020 restated³ CORE definition: See appendix 38#39Continuing Business CHF million Full-Year 2020 Financial Highlights (1/2) FY 2020 FY 2019 (Restated)1 YOY Sales 4,508 4,207 7.2%2 CORE EBITDA 1,406 1,334 5.4% Margin in % 31.2 31.7 (50bps) CORE EBIT 1,094 1,044 4.8% Margin in % 24.3 24.8 EBITDA 1,378 1,264 Margin in % 30.6 30.0 (50bps) 9.0% 60bps EBIT Margin in % Net Financing Costs Tax Rate in % 901 825 9.2% 20.0 19.6 40bps (94) (104) 8.8 9.9 CORE Profit for the Period Profit for the Period 913 851 7.3% 732 648 13.0% 1 Restated to reflect the classification of Specialty Ingredients as discontinued operations 2 Actual exchange rate (AER); in constant exchange rate (CER): +12.0% CORE definition: See appendix 39#40Continuing Business CHF million Full-Year 2020 Financial Highlights (2/2) FY 2020 FY 2019 (Restated)1 YOY CORE EPS basic (CHF) 12.24 11.47 6.7% EPS Basic (CHF) 9.81 8.73 12.4% CORE EPS Diluted (CHF) 12.19 11.40 6.9% EPS Diluted (CHF) 9.77 8.68 12.6% CORE RONOA in % 28.9 32.1 ROIC in % 9.6 9.2 Change of Net Working Capital (260) (234) (320bps) 40bps (26) Capital Expenditures (889) (693) (196) Operational Free Cash Flow 504 371 133 Number of Employees 13,856 12,718 8.9% Total Group² CHF million Net debt Debt-equity ratio Net Debt/ CORE EBITDA ratio FY 2020 FY 2019 YOY 2,813 2,961 (5.0%) 0.41 0.45 (8.9%) 1.63 1.83 (10.9%) 1 Restated to reflect the classification of Specialty Ingredients as discontinued operations 2 Lonza Group incl. Discontinued Operations) CORE definition: See appendix 41#41Event Calendar and Contacts 25 March 2021 6 May 2021 10 May 2021 11 May 2021 12 May 2021 23 July 2021 Annual Report 2020 (Tentative) Annual General Meeting, Basel (CH) Ex-Dividend Date Record-Dividend Date Dividend-Payment Date Half-Year Results 2021 For Investors Inquiries: Dirk Oehlers Investor Relations Officer +41 61 851 4927 [email protected] Information about investor relations events is constantly updated on the website: www.lonza.com/about-lonza/investor-relations For Media Inquiries: Victoria Morgan Associate Director, External Communications T +41 61 316 2283 [email protected] 42#42CORE Definition Lonza believes that disclosing CORE results of the Group's performance enhances the financial markets' understanding of the company because the CORE results enable better comparison across years. " Therefore, the CORE results exclude exceptional expenses and income related to e.g. restructuring, environmental-remediation, acquisitions and divestitures, impairments and amortization of acquisition-related intangible assets, which can differ significantly from year to year. For this same reason, Lonza uses these CORE results in addition to IFRS as important factors in internally assessing the Group's performance. In Lonza's 2020 Full-Year Results report, the reconciliation of IFRS to CORE results provides further details on the adjustments. 43#43Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX- ST Listing Manual. Forward-looking statements contained herein are qualified in their entirety as there are certain factors that could cause results to differ materially from those anticipated. Any statements contained herein that are not statements of historical fact (including statements containing the words "outlook," "guidance," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should be considered to be forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainty. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the timing and strength of new product offerings; pricing strategies of competitors; the company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; difficulty to maintain relationships with employees, customers and other business partners; and changes in the political, social and regulatory framework in which the company operates, or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. In particular, the assumptions underlying the Outlook 2021 and Mid- Term Guidance 2023 herein may not prove to be correct. The statements in the section on Outlook 2021 and Mid-Term Guidance 2023 constitute forward-looking statements and are not guarantees of future financial performance. Lonza's actual results of operations could deviate materially from those set forth in the section on Outlook 2021 and Mid-Term Guidance 2023 as a result of the factors described above or other factors. Investors should not place undue reliance on the statements in the section on Outlook 2021 and Mid-Term Guidance 2023. Except as otherwise required by law, Lonza disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after this presentation was published. 44